Latest / Morning Medical with Dr. Chow / Walking, GLP-1 Nail Risks, New Weight Loss Therapies, and Type 2 Diabetes

Transcript

Walking, GLP-1 Nail Risks, New Weight Loss Therapies, and Type 2 Diabetes · Morning Medical with Dr. Chow

• 0:00
  Welcome to Morning Medical with Dr.
• 0:02
  Chow, your daily dose of the latest in health and medical news from around the globe, powered
• 0:07
  by artificial intelligence.
• 0:09
  I'm your host, Dr.
• 0:10
  Chi-Ming Chow.
• 0:12
  Today, we're diving into some fascinating findings about walking and its impact on
• 0:16
  longevity.
• 0:17
  Let's get started!
• 0:21
  A new study published by the British Journal of Sports Medicine suggests that walking more or
• 0:27
  walking faster can lead to a longer life.
• 0:31
  This research analyzed data from 64,743 adults in the United Kingdom, with an average age of
• 0:39
  62.
• 0:41
  Participants wore wrist activity trackers for a week to monitor their daily step counts and
• 0:46
  walking pace.
• 0:48
  The researchers followed up with these participants over an average period of eight
• 0:53
  years.
• 0:54
  During this time, they recorded 1,697 deaths, including 502 from cardiovascular disease.
• 1:02
  The study categorized daily step counts into four groups: less than 5,000; 5,000 to 7,500;
• 1:10
  7,500 to 10,000; and more than 10,000 steps per day.
• 1:16
  Interestingly, the study found that individuals who walked fewer than 5,000 steps per day but
• 1:22
  at a faster pace had a significantly lower risk of dying from cardiovascular or other causes
• 1:28
  compared to those who walked less than 5,000 steps at a slower pace.
• 1:32
  In fact, their risk was similar to those walking between 5,000 and 7,500 steps per day
• 1:38
  at a slower pace.
• 1:40
  The lowest death rates were seen in those who took 7,500 to 10,000 steps per day.
• 1:46
  For maximizing longevity benefits, the study suggests aiming for a brisk walking pace of at
• 1:53
  least 90 to 100 steps per minute for 30 minutes daily.
• 1:57
  However, the authors also highlight that flexible combinations of step counts and speed
• 2:03
  can be beneficial for those with time or ability constraints.
• 2:08
  Walking is a simple, accessible way to meet exercise goals, and this study reinforces its
• 2:15
  potential benefits for a longer, healthier life.
• 2:20
  So, whether you're aiming to increase your step count or pick up the pace, incorporating
• 2:25
  walking into your routine could be a step in the right direction for your health.
• 2:31
  Next up, let's talk about a new study that raises some interesting questions about the
• 2:36
  side effects of GLP-1 receptor agonists, a class of drugs commonly used for managing type
• 2:43
  two diabetes and obesity.
• 2:46
  According to research presented at the European Academy of Dermatology and Venereology meeting,
• 2:51
  these medications may be linked to an increased risk of nail disorders, particularly
• 2:56
  onycholysis, which is the separation of the fingernails or toenails.
• 3:02
  The study looked at 575 users of GLP-1 receptor agonists and compared them to over a thousand
• 3:09
  individuals with obesity or type two diabetes who were not taking these drugs.
• 3:15
  The findings showed that 39.3 percent of those on GLP-1 agonists experienced onycholysis,
• 3:23
  compared to just 8.7 percent of the control group.
• 3:27
  This translates to a 4.5-fold higher likelihood of experiencing this nail disorder for those on
• 3:35
  the medication.
• 3:37
  In addition, nail discoloration, or dyschromia, was noted in 45.6 percent of GLP-1 users,
• 3:44
  compared to 17 percent of those not on the drugs, indicating a 2.7-fold increased risk.
• 3:52
  Other issues like nail fragility and the presence of ridges or grooves were also more
• 3:56
  common among those taking GLP-1 receptor agonists.
• 4:01
  Even after adjusting for factors such as comorbidities and nutritional deficiencies, the
• 4:06
  study still found a significant association between GLP-1 use and nail disorders.
• 4:12
  However, it is worth noting that nearly half of the participants had a history of nail problems
• 4:17
  before starting the medication.
• 4:19
  Interestingly, when the researchers focused only on new-onset nail problems, the difference
• 4:24
  between GLP-1 users and non-users disappeared.
• 4:28
  The study's lead investigator, Doctor Bianca Maria Piraccini from the University of Bologna,
• 4:35
  suggests that while there seems to be a clear association, the direct effect of the drugs
• 4:41
  cannot be ruled out.
• 4:43
  She emphasizes the importance for clinicians to monitor nail health in patients on these
• 4:49
  medications and to consider the possibility of a drug effect if new nail issues arise.
• 4:55
  Doctor Charles Taieb, a co-investigator, highlights that this is one of the first
• 5:00
  large-scale studies to examine the nail and hair effects of GLP-1 receptor agonists.
• 5:06
  He notes that while the findings show a clear association, they also underline the complexity
• 5:11
  of linking every change directly to the drug itself.
• 5:15
  Doctor Joe Tung from the University of Pittsburgh Medical Center, who was not involved
• 5:19
  in the study, advises patients not to be overly concerned if they're doing well on GLP-1
• 5:25
  medications.
• 5:27
  He suggests consulting a dermatologist if nail changes occur, as many common causes of nail
• 5:33
  disorders are treatable.
• 5:35
  Overall, the study provides a basis for further research into the potential side effects of
• 5:41
  GLP-1 drugs on nail health.
• 5:44
  It's a reminder of the importance of considering all aspects of medication effects,
• 5:49
  especially in treatments as widely used as these.
• 5:54
  In a recent phase IIb clinical trial, adults with type two diabetes experienced remarkable
• 6:01
  weight loss using an investigational combination therapy of eloralintide and
• 6:07
  tirzepatide.
• 6:09
  The trial, presented at the European Association for the Study of Diabetes annual
• 6:14
  meeting in Milan, highlighted the potential of this new drug combination to significantly aid
• 6:19
  in weight management for those with type two diabetes.
• 6:23
  The study involved a ten-arm trial, where participants on the highest tested dose of
• 6:28
  eloralintide plus tirzepatide lost an impressive 23.3 percent of their body weight
• 6:34
  over a period of 48 weeks.
• 6:36
  This was notably higher compared to the 14.8 percent weight loss seen with tirzepatide
• 6:42
  alone.
• 6:43
  Doctor Liana Billings from Endeavor Health in Evanston, Illinois, noted that these results
• 6:48
  offer hope for continued weight reduction.
• 6:51
  Tirzepatide, a dual GIP and GLP-1 receptor agonist, is already recognized for its efficacy
• 6:58
  in managing type two diabetes and weight.
• 7:01
  However, the addition of eloralintide, a selective amylin receptor agonist, appears to
• 7:07
  enhance the weight loss effects beyond what has been observed with tirzepatide alone.
• 7:11
  Billings mentioned that the weight loss achieved with this combination is comparable to
• 7:16
  results seen in metabolic surgery, a significant benchmark for weight management.
• 7:21
  The combination therapy works by simultaneously activating three hormone pathways—GIP, GLP-1,
• 7:27
  and amylin—each playing a role in regulating hunger and blood sugar after eating.
• 7:31
  Eli Lilly, the developer of this combination agent, emphasizes its potential to personalize
• 7:37
  treatment for patients by addressing both weight loss and glucose control through various
• 7:41
  doses and combinations.
• 7:44
  In addition to weight loss, the trial showed that nearly all participants in the
• 7:48
  highest-dose combination group achieved an HbA1c level below 7 percent, a standard goal
• 7:55
  for blood sugar control in diabetes management.
• 7:58
  Impressively, a significant portion of participants even reached HbA1c levels below
• 8:03
  5.7 percent, indicating normoglycemia.
• 8:07
  Despite these promising results, the trial also revealed some challenges.
• 8:12
  A high number of participants in the highest-dose combination group experienced
• 8:16
  treatment-emergent adverse events, with 84 percent affected.
• 8:21
  Furthermore, 27 percent of participants discontinued treatment due to these adverse
• 8:25
  events, a stark contrast to the 2.9 percent discontinuation rate in the tirzepatide-alone
• 8:32
  group.
• 8:33
  The trial randomized 367 adults with obesity or overweight and type two diabetes across the
• 8:40
  United States and Argentina into ten groups, including a placebo group and various
• 8:46
  combinations of eloralintide and tirzepatide.
• 8:49
  Although the combination therapy currently requires two separate injections, efforts are
• 8:54
  underway to develop a single-shot formulation for convenience.
• 8:58
  While the trial reported one death in the lowest-dose combination group, investigators
• 9:03
  determined it was unrelated to the study drug.
• 9:06
  Eloralintide is also being tested as a standalone agent in phase III trials for
• 9:12
  obesity, and Eli Lilly plans to advance the combination therapy into phase III development
• 9:18
  by the end of the year.
• 9:21
  Let's shift our focus now to a significant development in Canada concerning the health
• 9:26
  support for residential school survivors.
• 9:29
  A new federal petition has been submitted to the House of Commons, calling for permanent
• 9:33
  funding for health resources for these survivors.
• 9:35
  This move is spearheaded by Leah Gazan, a Member of Parliament from Winnipeg Centre, who
• 9:41
  presented the petition on September 24th.
• 9:45
  The petition emphasizes the importance of making health resource funding permanent for
• 9:50
  survivors of Canada's residential school system.
• 9:53
  At the heart of this petition is the Indian Residential Schools Resolution Health Support
• 9:57
  Program, which currently provides cultural and emotional supports, such as traditional
• 10:02
  healing, peer support, and mental health counseling, to survivors and their families.
• 10:08
  However, the program is scheduled to end in March 2028.
• 10:13
  During a press conference in Ottawa, Leah Gazan was joined by survivors from across the
• 10:18
  country, where she expressed that if the government is truly committed to
• 10:22
  reconciliation, it should not withdraw the essential funding needed for healing and
• 10:28
  support.
• 10:30
  Survivors like Jeannie Ehaloak, who have experienced the long-term impacts of
• 10:34
  residential schools, stress the importance of these supports in addressing traumatic
• 10:39
  memories.
• 10:41
  In addition to the health support program, the petition also calls for permanent federal
• 10:45
  funding for the Residential Schools Missing Children Community Support Fund.
• 10:50
  This fund aids Indigenous communities in locating unmarked graves and conducting
• 10:56
  archival research.
• 10:58
  The urgency for this funding is highlighted by the fact that many survivors are aging and wish
• 11:04
  to pass on critical knowledge to future generations about their experiences.
• 11:10
  The struggle for consistent federal funding is not new, as various Indigenous groups across
• 11:16
  Canada have faced financial barriers in recent years.
• 11:20
  Earlier this year, it was reported that ground searches at residential schools were hampered
• 11:26
  due to cuts in federal funding.
• 11:28
  Survivors like Jeannie Ehaloak express that finding unmarked graves provides closure, even
• 11:34
  if the remains are not brought home.
• 11:36
  Leah Gazan has also renewed calls to criminalize residential school denialism.
• 11:42
  This comes in light of recent demonstrations by white nationalists on Indigenous lands,
• 11:48
  emphasizing the need for legal measures to prevent denial of the historical truths of
• 11:52
  residential schools.
• 11:54
  Gazan's petition, which closed on September 2nd with 930 signatures, awaits a response from the
• 12:00
  federal government, which typically takes 45 days to address such petitions.
• 12:06
  This petition and the calls for permanent funding represent a crucial step toward
• 12:11
  ensuring that residential school survivors receive the necessary support to heal and
• 12:17
  preserve their history for future generations.
• 12:21
  It is a poignant reminder of the ongoing journey toward reconciliation and the
• 12:26
  importance of acknowledging and addressing past injustices.
• 12:31
  That wraps up today's episode of Morning Medical with Dr.
• 12:35
  Chow.
• 12:37
  Thank you for joining me as we explored these important topics.
• 12:41
  Remember, staying informed is a vital part of maintaining our health and well-being.
• 12:46
  Until next time, take care and stay healthy.